---

🧠 CLONUS — Complete Clinical Overview

---

1. DEFINITION

Clinically: sustained tendon stretch → rhythmic oscillations at 5–8 Hz that persist as long as the stretch is maintained.

---

2. TYPES / FEATURES

• Hyperreflexia
• Babinski sign (extensor plantar response)
• Spasticity (velocity-dependent increase in muscle tone)
• Weakness (pyramidal distribution)
• Absent superficial abdominal reflexes

---

3. CAUSES

🔴 Central Nervous System (UMN Lesions)

🟡 Metabolic / Toxic

• Hypocalcemia (causes neuromuscular hyperexcitability)
• Eclampsia / severe hypomagnesemia
• Serotonin syndrome (drug-induced hyperreflexia + clonus)
• Strychnine poisoning
• Neonatal drug withdrawal

---

4. PATHOPHYSIOLOGY

NORMAL PHYSIOLOGY:
Muscle Stretch
    ↓
Ia afferent fibers (muscle spindle)
    ↓
Alpha motor neuron in anterior horn
    ↓
Muscle contraction (monosynaptic stretch reflex)
    ↓
MODULATED by supraspinal corticospinal inhibition

CLONUS MECHANISM (UMN LESION):
Loss of corticospinal inhibitory signals
    ↓
Alpha motor neuron HYPEREXCITABILITY
    ↓
Increased muscle spindle (Ia afferent) sensitivity
    ↓
Stretch reflex threshold LOWERED
    ↓
Sustained stretch → Ia fires → alpha MN fires → muscle contracts
    ↓
Muscle shortens → Ia silenced → alpha MN relaxes → muscle relaxes
    ↓
Relaxation = re-stretching → Ia fires again
    ↓
RHYTHMIC OSCILLATION (5–8 Hz) = CLONUS

1. Loss of supraspinal inhibition — corticospinal tract lesion removes tonic descending inhibition on spinal interneurons
2. Increased Ia afferent excitability — lowered threshold of muscle spindle afferents
3. Decreased Ib (Golgi tendon organ) inhibitory input — normally limits reflex; impaired in spasticity
4. Interneuronal disinhibition — Ia inhibitory interneurons become hyperactive, amplifying reflex

---

5. CLINICAL EXAMINATION

Ankle Clonus (Most Common)

1. Patient supine, knee slightly flexed
2. Support the leg under the calf
3. Rapidly dorsiflex the foot and maintain the stretch
4. Positive: rhythmic beats of plantarflexion-dorsiflexion

Knee (Patellar) Clonus

1. Patient supine, leg extended
2. Grasp the patella between thumb and forefinger
3. Sharply push it distally and maintain downward pressure
4. Positive: rhythmic contractions of quadriceps visible/felt

Grading

---

6. INVESTIGATIONS

First-Line

Second-Line / Specialized

Harrison's Principles (p. 751): "Investigations typically begin with spinal MRI, but when UMN signs are associated with drowsiness, confusion, seizures, or other hemispheric signs, brain MRI should also be performed."

---

7. MANAGEMENT

🎯 Principle: Treat the Underlying Cause First

💊 Pharmacological Management of Spasticity/Clonus

💉 Interventional

🏃 Physiotherapy & Rehabilitation

• Stretching exercises — maintain range of motion, reduce contractures
• Splinting / orthoses — ankle-foot orthosis (AFO) prevents equinus deformity
• Hydrotherapy — warm water reduces spasticity
• Functional electrical stimulation (FES) — modulates spinal cord excitability
• TENS — reduces clonus via sensory modulation
• Constraint-induced movement therapy (CIMT) — post-stroke rehabilitation

---

8. COMPLICATIONS (If Untreated)

• Contractures — fixed joint deformities
• Pressure sores — from immobility
• Falls and injury — from unpredictable limb spasms
• Pain — painful muscle spasms
• Functional disability — impaired gait, ADLs
• Psychological impact — depression, reduced QoL

---

9. SUMMARY FLOWCHART

Patient presents with rhythmic involuntary limb contractions
                    ↓
         Elicit clonus clinically
         (ankle/knee/wrist)
                    ↓
    Sustained ≥4 beats → PATHOLOGICAL
                    ↓
      Look for other UMN signs:
   Hyperreflexia + Babinski + Spasticity
                    ↓
        Localize the lesion:
   Brain (+ cortical signs) vs Spinal cord
                    ↓
        ┌───────────────────────────────┐
        │    MRI Brain / Spine           │
        │    + Blood investigations      │
        │    + EMG/NCS if needed         │
        └───────────────────────────────┘
                    ↓
        Treat underlying cause
                    ↓
    Symptom control: Baclofen/Tizanidine
                    ↓
    Physiotherapy + Rehabilitation

---

10. KEY DIFFERENTIALS

---

Note: If you meant a different "clinia" term (e.g., Cholinergic Crisis, Colitis, Cholera, or another condition), please clarify and I'll provide a full detailed breakdown of that topic instead.

---

🧠 GUILLAIN-BARRÉ SYNDROME (GBS) — Complete Clinical Overview

---

1. DEFINITION

Harrison's Principles of Internal Medicine, 21st Ed. (p. 12718): "GBS is an acute, frequently severe, and fulminant polyradiculoneuropathy that is autoimmune in nature. It occurs year-round at a rate of between 10–20 cases per million annually."

• Incidence: 10–20 per million per year worldwide
• ~5,000–6,000 cases/year in the United States
• Males slightly more affected than females
• Bimodal age distribution: young adults (15–35 yrs) and elderly (50–75 yrs)
• Leading cause of acute flaccid paralysis in post-polio era

---

2. CAUSES & TRIGGERING FACTORS

🦠 Infectious Triggers

💉 Non-Infectious Triggers

---

3. PATHOPHYSIOLOGY

Molecular Mimicry — Core Mechanism

STEP 1: PRECEDING INFECTION
Campylobacter jejuni / Virus infects patient
         ↓
STEP 2: IMMUNE ACTIVATION
T-cells and B-cells activated against pathogen antigens
         ↓
STEP 3: MOLECULAR MIMICRY
Pathogen surface antigens (e.g., LOS of C. jejuni)
structurally resemble gangliosides on peripheral nerve myelin
(GM1, GD1a, GQ1b, GT1a)
         ↓
STEP 4: AUTOANTIBODY PRODUCTION
IgG anti-ganglioside antibodies produced
         ↓
STEP 5: COMPLEMENT ACTIVATION
Antibodies bind to Nodes of Ranvier / myelin sheath
→ Complement cascade activated (C3b, C5b-9 MAC)
         ↓
STEP 6: NERVE DAMAGE
① Demyelination → slowed conduction (AIDP)
② Axonal damage → lost conduction (AMAN/AMSAN)
         ↓
STEP 7: CLINICAL SYNDROME
Ascending weakness, areflexia, sensory loss,
autonomic dysfunction, respiratory failure

Histopathology

• AIDP: Lymphocytic infiltration + macrophage-mediated demyelination of peripheral nerves and roots; segmental demyelination
• AMAN: IgG/complement attack on nodal axolemma at Nodes of Ranvier; axonal degeneration without demyelination
• AMSAN: Same as AMAN but includes sensory axons; severe, poor recovery

---

4. GBS VARIANTS

---

5. CLINICAL FEATURES

🔺 Typical Presentation Timeline

WEEK 1–2: PRODROME
Preceding infection (URTI, gastroenteritis)
         ↓
DAY 1–7: ONSET
Tingling / paresthesias in toes and fingertips
Mild symmetric limb weakness (distal → proximal)
         ↓
WEEK 1–4: PROGRESSION PHASE
Ascending flaccid paralysis
Areflexia (loss of tendon reflexes)
Pain (back pain, radicular pain) — often early
         ↓
WEEK 2–4: PLATEAU PHASE
Maximum weakness reached
~25–30% require mechanical ventilation
         ↓
WEEKS TO MONTHS: RECOVERY PHASE
Slow recovery from proximal to distal

🔴 Motor Features

• Ascending bilateral symmetric weakness — starts in lower limbs, ascends to trunk, arms, cranial muscles
• Flaccid paralysis — reduced tone (contrast with UMN spasticity)
• Areflexia (hallmark) — absent deep tendon reflexes bilaterally
• Respiratory muscle weakness → may need ventilator (~25–30%)
• Facial diplegia (~50%) — bilateral LMN facial nerve palsy
• Oculomotor palsy — especially in Miller Fisher variant
• Bulbar weakness — dysphagia, dysphonia (risk of aspiration)
• Neck flexor weakness — patient cannot lift head off pillow

🟡 Sensory Features

• Glove-and-stocking paresthesias — tingling, numbness (distal)
• Back pain and radicular pain — often the first symptom
• Proprioceptive loss — unsteady gait
• Pain — often severe, neuropathic in nature; early and prominent feature
• Sensory loss often LESS severe than motor loss

🟠 Autonomic Features (in ~70% of cases)

⚠️ Autonomic dysfunction is a major cause of death in GBS — requires continuous cardiac monitoring in ICU.

🔵 Cranial Nerve Features

📋 Brighton Collaboration Diagnostic Criteria (2011)

---

6. INVESTIGATIONS

🔬 Cerebrospinal Fluid (CSF) Analysis — Most Important

Albuminocytologic dissociation = high protein + normal cell count. This is the pathognomonic CSF finding of GBS.

⚡ Nerve Conduction Studies (NCS) + EMG

NCS are the most sensitive investigation — abnormal in >85% of cases within 2 weeks.

🩸 Blood Investigations

🖥️ Imaging

📈 Respiratory Monitoring (Critical)

---

7. MEDICAL MANAGEMENT

🚨 Phase 1: Emergency Stabilization & ICU Monitoring

On diagnosis of GBS:
1. ADMIT to monitored bed (HDU/ICU if moderate-severe)
2. RESPIRATORY: serial FVC q4-6h, pulse oximetry
3. CARDIAC: continuous ECG monitoring (autonomic dysfunction)
4. IV ACCESS + baseline bloods
5. URINARY CATHETER if retention
6. DVT PROPHYLAXIS: LMWH + compression stockings
7. NG TUBE if bulbar palsy / swallowing impaired
8. PAIN MANAGEMENT: neuropathic agents

💊 Specific Immunomodulatory Treatment

Option 1: Intravenous Immunoglobulin (IVIG) ✅ FIRST-LINE

Option 2: Plasma Exchange (Plasmapheresis / PE) ✅ EQUALLY EFFECTIVE

⚠️ IVIG + Plasmapheresis combined is NOT more effective than either alone (Dutch GBS Study Group). Do NOT combine routinely.

❌ Corticosteroids are NOT beneficial in GBS — multiple RCTs have shown no benefit; they may even delay recovery. Do NOT use steroids in GBS.

📊 IVIG vs Plasmapheresis Comparison

💊 Supportive Medical Management

Pain Management

Autonomic Dysfunction

Respiratory Support

DVT / PE Prevention

• LMWH (e.g., enoxaparin 40 mg SC OD) — started early
• Graduated compression stockings
• Intermittent pneumatic compression
• Early mobilization when possible

Nutrition

• NG feeding if dysphagia/bulbar palsy
• High-protein diet to support nerve recovery
• Vitamin B12 monitoring and supplementation

Psychological Support

• GBS is extremely distressing — rapid paralysis with preserved consciousness
• Regular reassurance of expected recovery
• Psychiatric liaison if severe anxiety/depression
• Patient and family education

---

8. SURGICAL / INTERVENTIONAL MANAGEMENT

🔧 Surgical / Procedural Interventions

1. Tracheostomy

2. Central Venous Access (for Plasmapheresis)

• Double-lumen central venous catheter (internal jugular or femoral)
• Required for adequate blood flow during plasma exchange (>150 mL/min)
• Placed under USS guidance in ICU or radiology suite
• Complications: infection, pneumothorax, thrombosis

3. Percutaneous Endoscopic Gastrostomy (PEG)

4. Urinary Catheterization (Surgical Cystostomy)

• If prolonged urinary retention and urethral catheter not tolerated
• Suprapubic cystostomy placed surgically or percutaneously

5. Surgical Management of Complications

6. Cardiac Pacing

• Temporary transcutaneous/transvenous pacing for severe autonomic bradycardia / complete heart block
• A cardiology/electrophysiology consult required
• Permanent pacemaker rarely needed — autonomic dysfunction typically resolves

---

9. DISABILITY GRADING SCALE (GBS-DS)

Treat with IVIG or PE if Grade ≥ 3 (cannot walk independently) or if deteriorating rapidly.

---

10. COMPLICATIONS

---

11. PROGNOSIS

Poor Prognostic Factors

• Age > 60 years
• Rapid progression (nadir within 1 week)
• Preceding C. jejuni infection
• AMAN/AMSAN variant
• Need for mechanical ventilation
• Low CMAP amplitude on NCS
• Axonal loss on EMG

---

12. DIFFERENTIALS TO EXCLUDE

---

13. SUMMARY ALGORITHM

Acute ascending flaccid paralysis + areflexia
              ↓
Exclude spinal cord compression (MRI spine)
              ↓
CSF: Albuminocytologic dissociation (↑protein, normal cells)
NCS/EMG: Demyelinating or axonal pattern
              ↓
DIAGNOSE GBS
              ↓
ASSESS SEVERITY (GBS Disability Scale)
              ↓
      ┌────────────────────────────────────────┐
      │      IMMEDIATE ICU/HDU admission       │
      │  Serial FVC every 4–6 hours            │
      │  Continuous cardiac monitoring         │
      │  DVT prophylaxis                       │
      └────────────────────────────────────────┘
              ↓
SPECIFIC TREATMENT (if Grade ≥3 or deteriorating):
   ┌─────────────────────┬─────────────────────┐
   │ IVIG 0.4 g/kg/day   │ Plasmapheresis      │
   │ × 5 days IV         │ 5 exchanges/10 days │
   │ (First-line, easier)│ (Equally effective) │
   └─────────────────────┴─────────────────────┘
   (Do NOT combine; Do NOT use steroids)
              ↓
SUPPORTIVE:
   Pain control | Autonomic monitoring
   Nutrition | Physiotherapy | Psychological support
              ↓
MONITOR FOR RESPIRATORY FAILURE:
   FVC < 20 mL/kg → Elective intubation
   Bulbar palsy → Early intubation
              ↓
SURGICAL (if needed):
   Tracheostomy | PEG | Central line | Pacing
              ↓
REHABILITATION:
   Physiotherapy | OT | Speech therapy
   Graded mobilization | AFO if foot drop

---

• Harrison's Principles of Internal Medicine, 21st Edition (pp. 12718, 12724)
• Brighton Collaboration GBS Diagnostic Criteria (2011)
• Dutch GBS Study Group — IVIG vs Plasmapheresis RCT
• European Academy of Neurology / Peripheral Nerve Society GBS Guidelines

---

🧠 HEAD INJURY (Traumatic Brain Injury) — Complete Clinical Overview

---

1. DEFINITION

Bailey & Love's Short Practice of Surgery, 28th Ed. (p. 381): "TBI can be considered as the combination of primary injury sustained on impact, and hence not medically modifiable, and secondary injury developing in the following hours and days. Understanding the importance of intracranial pressure (ICP) and related parameters is key to minimising secondary injury and improving outcomes."

• Leading cause of death and disability in persons aged 1–45 years
• Worldwide incidence: ~69 million TBIs per year
• Males affected 2–3× more than females
• Bimodal peak: young adults (15–24 yrs) and elderly (>65 yrs)
• Road traffic accidents are the most common cause globally

---

2. CAUSES

---

3. CLASSIFICATION

3A. By Severity — Glasgow Coma Scale (GCS)

GCS ≤ 8 = comatose → requires airway protection (intubation)

3B. By Structural Nature

3C. By Pathological Type

3D. By Mechanism

---

4. PATHOLOGY

4A. Primary vs Secondary Brain Injury

PRIMARY BRAIN INJURY (Immediate — NOT reversible)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Occurs at moment of impact
• Skull fracture
• Cerebral contusion/laceration
• Diffuse axonal injury (DAI)
• Acute intracranial hemorrhage (EDH, SDH, SAH, ICH)
• Direct neuronal death

SECONDARY BRAIN INJURY (Hours to days — PREVENTABLE)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Systemic: Hypoxia (SpO₂ <90%), Hypotension (SBP <90 mmHg),
          Hyperthermia, Hypoglycemia, Hypo/hypernatremia
Intracranial: Raised ICP, Cerebral edema, Vasospasm,
              Excitotoxicity (glutamate), Free radical damage,
              Herniation, Seizures, Infection

Key principle: Primary injury cannot be reversed; all treatment targets secondary injury prevention.

4B. Monro-Kellie Doctrine

• Brain parenchyma: 80% (~1200 mL)
• Blood (arterial + venous): 10% (~150 mL)
• CSF: 10% (~150 mL)

1. CSF displaced to spinal subarachnoid space
2. Venous blood displaced to jugular veins
3. Once exhausted → ICP rises exponentially

Normal ICP: 7–15 mmHg; Treatment threshold: >20–22 mmHg

CPP = MAP − ICP
Target CPP: 60–70 mmHg

---

4C. Specific Pathological Entities

1. 💀 Skull Fractures

---

2. 🔴 Extradural (Epidural) Hematoma (EDH)

---

3. 🟣 Subdural Hematoma (SDH)

---

4. 🟡 Subarachnoid Hemorrhage (SAH) — Traumatic

---

5. 🔵 Cerebral Contusion

---

6. ⚡ Diffuse Axonal Injury (DAI)

---

7. 💥 Concussion

---

5. CLINICAL FEATURES

5A. Initial Assessment — ATLS ABCDE Approach

A — Airway: Secure airway; C-spine immobilisation
B — Breathing: Ensure adequate ventilation; SpO₂ >95%
C — Circulation: IV access x2; BP maintenance; hemorrhage control
D — Disability: GCS, pupils, limb movement
E — Exposure: Full examination; log roll

5B. Symptoms by Severity

5C. Localizing Signs

5D. Herniation Syndromes

---

6. INVESTIGATIONS

6A. CT Head — NICE Criteria (Immediate CT within 1 hour)

6B. CT Head Findings

6C. MRI Brain

6D. Blood Investigations

6E. Other Investigations

---

7. MEDICAL MANAGEMENT

7A. Pre-hospital / Emergency Department

1. AIRWAY — Jaw thrust (not head tilt in trauma); C-spine collar
   GCS ≤ 8 → RSI intubation (rapid sequence intubation)
   Target SpO₂ > 95%; PaO₂ > 13 kPa

2. BREATHING — Controlled ventilation
   Target PaCO₂ 35–40 mmHg (normocapnia)
   Avoid hypocapnia (causes vasoconstriction → ischemia)
   Avoid hypercapnia (causes vasodilation → raises ICP)

3. CIRCULATION — Two large-bore IVs
   Target SBP > 100 mmHg (age 50-69) or > 110 mmHg (age 15-49, >70)
   Avoid hypotension (SBP < 90 → doubles mortality)
   Avoid hyponatraemia — use 0.9% NaCl not 5% dextrose
   Reverse coagulopathy: Vit K, FFP, platelets, TXA

4. DISABILITY — GCS every 30 min; pupil assessment
   Glucose control: target 6–10 mmol/L

5. ENVIRONMENT — Normothermia (temp > 38°C worsens outcome)

7B. ICU Management — Stepwise ICP Control

TIER 0 — Basic Neuroprotective Measures (All Severe TBI)

TIER 1 — First-Line ICP Reduction

TIER 2 — Osmotherapy

Hypertonic saline increasingly preferred over mannitol in hypotensive patients (mannitol causes diuresis → hypotension).

TIER 3 — Hyperventilation

TIER 4 — Barbiturate Coma (Refractory ICP)

TIER 5 — Temperature Control (Therapeutic Hypothermia)

7C. Specific Drug Treatments

---

8. SURGICAL MANAGEMENT

8A. Surgical Indications

---

8B. Surgical Procedures in Detail

1. 🔧 Burr Hole Craniotomy

1. Position patient supine or lateral; shave and prep scalp
2. Linear scalp incision over temporal region (for EDH)
3. Drill burr hole with Hudson brace or high-speed drill
   — Temporal burr hole: 2 cm anterior and superior to tragus
4. Dura cauterized and incised
5. Clot evacuated by suction and irrigation
6. Hemostasis; drain placed if needed
7. Closure in layers

---

2. 🏥 Trauma Craniotomy (Hematoma Evacuation)

1. General anesthesia; head pinned in Mayfield clamp
2. Horseshoe/trauma flap scalp incision
   — Temporoparietal "trauma flap" for temporal EDH/SDH
3. Burr holes placed at corners of planned bone flap
4. Craniotome used to connect burr holes — bone flap elevated
5. Dura opened (cruciate or semicircular incision)
6. Hematoma evacuated:
   — EDH: Liquid + clot suctioned; bleeding vessel coagulated
   — SDH: Clot irrigated out with copious warm saline
7. Hemostasis with bipolar diathermy + Surgicel
8. Dura closed (primarily or with patch graft)
9. Bone flap replaced and fixed with titanium plates/screws
10. Wound closure in layers + drain

---

3. 🧠 Decompressive Craniectomy

1. Large frontotemporo-parietal skin flap
2. Large bone flap (≥12 cm diameter) removed
   — Creates space for swollen brain to expand outward
3. DURAPLASTY: Dura opened widely + patch graft (pericranium,
   synthetic dura) sewn in to expand dural volume by 20-25%
   — Critical step: dura must be expanded, not just skin
4. Bone flap stored: cryopreserved (–80°C) OR abdominal
   subcutaneous pocket (to maintain viability)
5. Staged CRANIOPLASTY later (6–12 weeks) when brain swelling
   resolved: bone flap replaced or titanium mesh prosthesis

• Sinking skin flap syndrome (paradoxical herniation through defect)
• Hygroma formation
• Bone flap resorption
• CSF leak
• Infection

---

4. 📡 Intracranial Pressure (ICP) Monitoring

• Severe TBI (GCS 3–8) + abnormal CT scan
• Severe TBI + normal CT + ≥2 of: age >40, SBP <90, motor posturing

• A waves (plateau waves): ICP 50–100 mmHg for 5–20 min → critical; impending herniation
• B waves: ICP 20–50 mmHg for 0.5–2 min → pathological; raised ICP
• C waves: Minor oscillations; physiological

---

5. 💧 External Ventricular Drain (EVD)

1. Kocher's point: 1 cm anterior to coronal suture,
   2.5 cm lateral to midline (mid-pupillary line)
2. Burr hole at Kocher's point
3. Dura punctured; catheter directed perpendicular to brain
   surface, aimed at medial canthus of ipsilateral eye
   and ipsilateral tragus (toward foramen of Monro)
4. Catheter advanced 5–7 cm → CSF flows
5. Tunneled subcutaneously; connected to closed drainage system
6. Zeroed at level of foramen of Monro (tragus)

---

6. 🦴 Elevation of Depressed Skull Fracture

• Depression > full skull thickness
• Open (compound) fracture
• Underlying hematoma
• Cosmetic deformity
• Dural breach / pneumocephalus

1. Elliptical scalp incision around fracture
2. Burr hole placed adjacent (away from fracture)
3. Fragments carefully elevated using dissector/periosteal elevator
4. Dura inspected; repaired if lacerated
5. Thorough debridement of contaminated wounds
6. Irrigation with antibiotic solution
7. Bone fragments replaced and fixed if non-contaminated
8. Open/contaminated fractures: fragments discarded;
   cranioplasty deferred 6 months
9. IV antibiotics: Co-amoxiclav 1.2g TDS x 5 days

---

9. COMPLICATIONS

Early Complications (Hours–Days)

Late Complications (Weeks–Months)

---

10. PROGNOSIS — Glasgow Outcome Scale (GOS)

• GCS ≤ 3 on admission (especially motor score = 1)
• Bilateral fixed dilated pupils
• Age > 60 years
• Hypotension + hypoxia on admission
• CT: effaced basal cisterns, bilateral hemorrhages, SAH
• DAI Grade 3 (brainstem involvement)
• Prolonged ICP > 40 mmHg

---

11. SUMMARY MANAGEMENT ALGORITHM

TRAUMA CALL — Head Injury Patient
             ↓
ATLS: Airway (C-spine) → Breathing → Circulation
             ↓
GCS Assessment + Pupil Exam
             ↓
         ┌─────────────────────────────────┐
         │ GCS 13-15 (Mild)               │
         │ Observe; CT if NICE criteria   │
         │ Discharge if CT normal + well  │
         └─────────────────────────────────┘
             ↓
         ┌─────────────────────────────────┐
         │ GCS 9-12 (Moderate)            │
         │ CT HEAD + C-spine              │
         │ Admit to HDU; serial GCS       │
         │ Neurosurgical referral         │
         └─────────────────────────────────┘
             ↓
         ┌─────────────────────────────────┐
         │ GCS ≤ 8 (Severe)               │
         │ RSI Intubation                 │
         │ CT HEAD immediately            │
         │ Neurosurgical ICU              │
         │ ICP monitoring                 │
         └─────────────────────────────────┘
             ↓
  CT shows mass lesion + mass effect?
         ↓                ↓
        YES               NO
         ↓                ↓
  EMERGENCY          Medical ICP
  SURGERY            Management
  Craniotomy/        (Tiered protocol)
  Burr hole          Tier 0→1→2→3→4
         ↓                ↓
  ICP refractory to all measures?
         ↓
  DECOMPRESSIVE CRANIECTOMY
         ↓
  ICU: Neuroprotection + Rehabilitation

---

• Bailey & Love's Short Practice of Surgery, 28th Ed. (pp. 381, 384)
• Harrison's Principles of Internal Medicine, 21st Ed. (p. 12563)
• Brain Trauma Foundation (BTF) Guidelines for Severe TBI, 4th Ed. (2016)
• NICE Head Injury Guidelines CG176 (2014, updated 2023)
• CRASH-3 Trial — Tranexamic acid in TBI (Lancet 2019)
• DECRA Trial — Decompressive craniectomy (NEJM 2011)
• RESCUEicp Trial (NEJM 2016)

---

🧠 STROKE & TIA — Complete Structured Clinical Answer

Covering Questions 3, 4, 5, 6 & 7

---

---

SECTION A: DEFINITION OF STROKE

"A rapidly developing episode of focal or global neurological dysfunction of vascular origin, lasting more than 24 hours or leading to death, with no apparent non-vascular cause."

"An infarction of the central nervous system (brain, spinal cord, or retinal cells) attributable to ischemia, based on neuropathological, neuroimaging, or clinical evidence."

• Duration > 24 hours OR death (if < 24 hours → TIA if no infarction on imaging)
• Must exclude metabolic causes (hypoglycemia, Todd's paresis, migraine, tumor)
• Also called Cerebrovascular Accident (CVA)

---

SECTION B: CLASSIFICATION OF STROKE

B1. By Pathological Type

B2. Ischemic Stroke — TOAST Classification

B3. Hemorrhagic Stroke

B4. By Vascular Territory

B5. Oxford (Bamford) Clinical Classification

---

SECTION C: CAUSES OF STROKE

Ischemic Causes

Hemorrhagic Causes

---

SECTION D: RISK FACTORS FOR STROKE / CVA

Modifiable Risk Factors

Non-Modifiable Risk Factors

---

SECTION E: EARLY WARNING SIGNS OF STROKE

BE-FAST Acronym

Other Early Warning Features

• Sudden severe headache with no known cause ("worst headache of life" → SAH)
• Sudden numbness or tingling in face, arm, or leg (especially one-sided)
• Sudden confusion or difficulty understanding
• Sudden dizziness, vertigo, or unsteady gait
• Sudden diplopia (double vision)
• Transient monocular blindness (amaurosis fugax) → carotid TIA

---

SECTION F: TRANSIENT ISCHEMIC ATTACK (TIA)

Definition

AHA/ASA 2009 (Tissue-Based Definition): "A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, WITHOUT acute infarction."

• Old time-based definition: symptoms resolve within 24 hours
• New definition: tissue-based — symptoms may be brief but imaging may show infarction
• Most TIAs last < 1–2 hours (AHA/ASA Guidelines)
• If symptoms last > 24 hours with NO infarction on imaging → still TIA by new definition
• If imaging unavailable and symptoms last > 24 hours → classified as clinical stroke

Clinical Features of TIA

ABCD² Score — Risk Stratification After TIA

Clinical Significance of TIA

1. Short-term stroke risk: 10–20% risk of stroke within 90 days; highest in first 48 hours (up to 10%)
2. "Stroke waiting to happen": TIA patients who present early and are managed aggressively have 80% reduction in subsequent stroke risk
3. SOS-TIA Clinic data: Urgent same-day evaluation and treatment can reduce 90-day stroke risk from ~10% to ~2%
4. Crescendo TIA: Multiple TIAs in rapid succession = imminent stroke; requires emergency hospital admission
5. Investigation window: Opportunity to find and treat the underlying cause before disabling stroke occurs

Investigations After TIA

Management of TIA

URGENT SAME-DAY ASSESSMENT (ABCD² ≥ 4 or multiple TIAs)
              ↓
IMMEDIATE ANTIPLATELET THERAPY:
Aspirin 300 mg STAT (loading dose)
then Aspirin 75 mg OD + Clopidogrel 75 mg OD (dual antiplatelet x 21 days)
— POINT study: dual antiplatelet ↓ early recurrence by 25%
              ↓
If AF confirmed → ANTICOAGULATION:
DOAC (apixaban/rivaroxaban/dabigatran) or Warfarin
              ↓
STATIN: Atorvastatin 80 mg OD (started same day)
              ↓
ANTIHYPERTENSIVE: If SBP > 130 → treat (after acute phase)
ACE inhibitor + thiazide (PROGRESS trial)
              ↓
CAROTID ENDARTERECTOMY: If 70–99% ipsilateral carotid stenosis
— Within 2 weeks of TIA (NASCET, ECST trials)
              ↓
LIFESTYLE: Smoking cessation, diet, exercise, alcohol reduction

---

SECTION G: ISCHEMIC vs HEMORRHAGIC STROKE — COMPARISON

---

SECTION H: ACUTE MANAGEMENT OF STROKE

H1. Pre-Hospital Phase

1. RECOGNITION: BE-FAST symptom identification
2. CALL emergency services IMMEDIATELY
3. NOTE exact time of symptom onset (or "last seen well")
4. DO NOT give aspirin until hemorrhage excluded by CT
5. EMS: Rapid transfer to stroke-capable hospital
   "Time is brain" — 1.9 million neurons lost per minute

H2. Emergency Department — First 60 Minutes ("Golden Hour")

0–10 min:  Stroke team alert; ABCDE assessment
           IV access x2; bloods (FBC, U&E, coag, glucose, group & save)
           12-lead ECG
           Pulse oximetry; O₂ if SpO₂ < 95%

0–25 min:  Urgent non-contrast CT brain
           (exclude hemorrhage before any antithrombotic therapy)

0–45 min:  CT reviewed by stroke physician/radiologist

0–60 min:  TREATMENT DECISION (door-to-needle < 60 min target)

H3. Acute Ischemic Stroke Management

Step 1 — Stabilization

Step 2 — IV Thrombolysis (Alteplase / tPA)

Step 3 — Mechanical Thrombectomy (Endovascular Treatment)

Step 4 — Antiplatelet Therapy

Step 5 — Stroke Unit Admission

• Nurse-led neurological observation (GCS, pupils, limb power) q1–4h
• Dysphagia screening before any oral intake (SALT referral)
• Physiotherapy: early mobilization within 24–48 hours
• Occupational therapy, speech and language therapy
• DVT prophylaxis: compression stockings; LMWH after 24–48 hours
• Bladder/bowel care; pressure area care
• Early rehabilitation planning

---

H4. Acute Hemorrhagic Stroke Management

Intracerebral Hemorrhage (ICH)

Subarachnoid Hemorrhage (SAH) Management

ISAT Trial: Coiling significantly better than clipping at 1 year (independent survival 23.7% vs 30.6% risk of dependency/death).

---

SECTION I: SECONDARY PREVENTION AFTER STROKE/TIA

---

SECTION J: COMPLICATIONS OF STROKE

---

SUMMARY COMPARISON TABLE — All 5 Questions Answered

---

• Harrison's Principles of Internal Medicine, 21st Ed. (p. 12293)
• AHA/ASA TIA Guidelines 2009 — "Adult Patients With Suspected TIA in the Emergency Department" (p. 2)
• NICE Stroke Guidelines NG128 (2019)
• ISAT Trial — Neurosurgery vs coiling for SAH (Lancet 2002)
• POINT / CHANCE Trials — Dual antiplatelet after TIA
• HERMES meta-analysis — Mechanical thrombectomy
• INTERACT2, ATACH-2 — Blood pressure in ICH
• NASCET/ECST — Carotid endarterectomy
• PROGRESS Trial — BP lowering after stroke